Drawing for CARMINGO

USPTO serial 90274250

CARMINGO

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
GRIFFIN, JAMES
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CARMINGO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kaitlyn Garvin

14 CEDAR STREET, SUITE 224AMESBURY, MA 01913UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations in the nature of indigo carmine solutions for marking tissue by injection in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable administration, for oral and topical antiseptic treatment, for marking and functional verification of gynecological and urological systems by instillation, injection or local application; Chemical preparations in the nature of indigo carmine for medical use for marking tissue by injection in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable administration, for oral and topical antiseptic treatment, for marking and functional verification of gynecological and urological systems by instillation, injection or local application; Chemical preparations in the nature of indigo carmine solutions for medical use for marking tissue by injection in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable administration, for oral and topical antiseptic treatment, for marking and functional verification of gynecological and urological systems by instillation, injection or local application; indigo carmine solutions for use as a marker during gastro-intestinal endoscopy; indigo carmine solutions used as a contrast solution for medical imaging procedures; indigo carmine solutions for medical diagnostic purposes for viewing and marking tissue; indigo carmine solutions used as an aid in visualization of topographic irregularities and in delineation of polypoid or flat lesions, including adenomas; indigo carmine solutions used for polyps or lesions resection medicines for tissue staining; indigo carmine solutions for use as a marker during visceral surgery; indigo carmine solutions for the detection of amniotic fluid leaks; indigo carmine solutions for use as a marker during cystoscopy and ureteral catheterization; indigo carmine solutions for use as a marker during vessel delineation and tumor localization procedures; clinical medical reagents; synthetic peptides for pharmaceutical use, namely, for cancer treatments, immunotherapy, cell therapy, antivirals and antibiotics; phytotherapy preparations for medical use; diagnostic preparations in vials for medical use; Drug delivery agents in the form of filled vials that facilitate the delivery of pharmaceutical preparations; pre-filled syringes for medical and clinical purposes, sold filled with indigo carmine solutions for marking tissue by injection application in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable, for the antiseptic treatment orally or topically, for marking and functional verification gynecological and urological systems, by instillation, injection or local application; all of these goods excluding food supplements, hand sanitizing preparations, insect repellents and bone growth mediaACTIVE—
010Medical apparatus and instruments for use in exploratory endoscopy procedures in surgery, gynecology, urology, gastroenterology and medical imaging procedures; apparatus and instruments for diagnostic purposes for medical use for use in surgery, gynecology, urology and gastroenterology proceduresACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Feb 22, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 21, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 20, 2021NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 25, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 25, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 5, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 19, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 19, 2021XAECEXAMINER'S AMENDMENT ENTERED—
Apr 19, 2021GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Apr 19, 2021GNEAEXAMINERS AMENDMENT E-MAILED—
Apr 19, 2021CNEAEXAMINERS AMENDMENT -WRITTEN—
Apr 15, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 15, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 15, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 25, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 25, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 25, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 24, 2021DOCKASSIGNED TO EXAMINER—
Dec 11, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 27, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance